WO2003074073A3 - Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof - Google Patents

Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof Download PDF

Info

Publication number
WO2003074073A3
WO2003074073A3 PCT/FR2003/000695 FR0300695W WO03074073A3 WO 2003074073 A3 WO2003074073 A3 WO 2003074073A3 FR 0300695 W FR0300695 W FR 0300695W WO 03074073 A3 WO03074073 A3 WO 03074073A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
sequences
disorders
relates
applications
Prior art date
Application number
PCT/FR2003/000695
Other languages
French (fr)
Other versions
WO2003074073A2 (en
Inventor
Salman Al-Mahmood
Sylvie Colin
Christophe Schneider
Original Assignee
Gene Signal
Salman Al-Mahmood
Sylvie Colin
Christophe Schneider
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0202717A external-priority patent/FR2836686A1/en
Application filed by Gene Signal, Salman Al-Mahmood, Sylvie Colin, Christophe Schneider filed Critical Gene Signal
Priority to AU2003233359A priority Critical patent/AU2003233359A1/en
Priority to EP03727567A priority patent/EP1515742A2/en
Priority to JP2003572589A priority patent/JP2005532788A/en
Priority to CA002477662A priority patent/CA2477662A1/en
Publication of WO2003074073A2 publication Critical patent/WO2003074073A2/en
Priority to US10/934,998 priority patent/US7553492B2/en
Publication of WO2003074073A3 publication Critical patent/WO2003074073A3/en
Priority to US12/479,909 priority patent/US8133877B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

The invention relates to therapeutic compositions used in the field of angiogenesis, comprising nucleotide sequences of genes, the involvement of said genes in the angiogenesis mechanism having been demonstrated by the applicant, and including the complementary sequences thereof, the antisense sequences of same, polypeptide sequences coded by the coding parts of the aforementioned genes and antibodies that are directed against said polypeptide sequences. The invention also relates to genetically-modified cells that underexpress or overexpress the above-mentioned genes and to therapeutic compositions containing said cells, which are used to treat angiogenic disorders. Moreover, the invention relates to methods of diagnosing and/or prognosticating antiogenic disorders and to novel methods of screening active compounds in the treatment of said disorders.
PCT/FR2003/000695 2002-03-04 2003-03-04 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof WO2003074073A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2003233359A AU2003233359A1 (en) 2002-03-04 2003-03-04 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof
EP03727567A EP1515742A2 (en) 2002-03-04 2003-03-04 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof
JP2003572589A JP2005532788A (en) 2002-03-04 2003-03-04 Genes involved in regulation of angiogenesis, pharmaceutical compositions containing them, and uses thereof
CA002477662A CA2477662A1 (en) 2002-03-04 2003-03-04 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof
US10/934,998 US7553492B2 (en) 2002-03-04 2004-09-03 Pharmaceutical compositions containing angiogenic activators
US12/479,909 US8133877B2 (en) 2002-03-04 2009-06-08 Composition comprising an antisense sequence implicated in the regulation of angiogenesis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR02/02717 2002-03-04
FR0202717A FR2836686A1 (en) 2002-03-04 2002-03-04 Compositions containing nucleic acid or polypeptide differentially expressed in angiogenesis are useful to diagnose, prognose and treat angiogenic disorders including tumor vascularization and heart disease
FR02/04546 2002-04-11
FR0204546A FR2836687A1 (en) 2002-03-04 2002-04-11 GENES INVOLVED IN THE REGULATION OF ANGIOGENESIS, PHARMACEUTICAL PREPARATIONS CONTAINING SAME AND THEIR APPLICATIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/934,998 Continuation US7553492B2 (en) 2002-03-04 2004-09-03 Pharmaceutical compositions containing angiogenic activators

Publications (2)

Publication Number Publication Date
WO2003074073A2 WO2003074073A2 (en) 2003-09-12
WO2003074073A3 true WO2003074073A3 (en) 2005-01-13

Family

ID=27758815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/000695 WO2003074073A2 (en) 2002-03-04 2003-03-04 Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof

Country Status (7)

Country Link
US (2) US7553492B2 (en)
EP (3) EP2161280A3 (en)
JP (2) JP2005532788A (en)
AU (1) AU2003233359A1 (en)
CA (1) CA2477662A1 (en)
FR (1) FR2836687A1 (en)
WO (1) WO2003074073A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2449136A1 (en) * 2001-06-05 2002-12-12 Exelixis Inc. Igs as modifiers of the p53 pathway and methods of use
US7803906B2 (en) 2002-03-22 2010-09-28 Gene Signal International Sa Composition comprising an angiogenesis related protein
FR2837391B1 (en) * 2002-03-22 2007-04-20 Gene Signal REGULATORY GENES OF ANGIOGENESIS, PHARMACEUTICAL PREPARATIONS CONTAINING SAME AND APPLICATIONS THEREOF
JP4557886B2 (en) * 2003-08-11 2010-10-06 財団法人くまもとテクノ産業財団 Esophageal cancer antigens and their use
EP1591534A1 (en) * 2004-04-01 2005-11-02 Stichting Sanquin Bloedvoorziening A method of genotyping blood cell antigens and a kit suitable for genotyping blood cell antigens
FR2880631A1 (en) * 2005-01-10 2006-07-14 Gene Signal GENES INVOLVED IN THE REGULARIZATION OF ANGIOGENESIS, PHARMACEUTICAL PREPARATIONS CONTAINING SAME AND THEIR APPLICATIONS
WO2007069423A1 (en) * 2005-12-12 2007-06-21 Riken Diagnostic marker for allergy
EP1955705B1 (en) * 2007-02-09 2013-04-17 Gene Signal International Sa Wound healing agent and composition
EP1955704A1 (en) * 2007-02-09 2008-08-13 Gene Signal International Sa Wound healing agent and composition
US20080194478A1 (en) * 2007-02-09 2008-08-14 Gene Signal International Sa Wound healing agent and composition
US8372810B2 (en) 2007-04-11 2013-02-12 Gene Signal International Sa Anti-tumor drug, medicament, composition, and use thereof
EP1980571B1 (en) * 2007-04-11 2010-10-13 Gene Signal International Sa Anti-tumor drug, medicament, composition, and use thereof
CA2683463A1 (en) * 2007-04-11 2008-10-23 Gene Signal International Sa Anti-tumor variants and fragments of protein 497c, and uses thereof
AU2008249961B2 (en) 2007-05-16 2017-02-02 Gene Signal International Sa Anti-tumor drug, medicament, composition, and use thereof
US8288334B2 (en) * 2010-06-14 2012-10-16 Gene Signal International Sa Peptides for wound healing
WO2012135500A1 (en) 2011-03-29 2012-10-04 The General Hospital Corporation Engineered thioredoxin-like fold proteins
US9682144B2 (en) 2011-06-30 2017-06-20 Gene Signal International, Sa Composition comprising inhibitors of IRS-1 and of VEGF
CN102558311B (en) * 2012-02-13 2014-02-19 中山大学 Mutant protein of chronic virus B hepatitis correlated gene TMEM2, coding gene of mutant protein and application of coding gene
US20150005183A1 (en) * 2013-07-01 2015-01-01 Expression Pathology, Inc. Protein biomarkers of late stage breast cancer
US10385096B2 (en) * 2016-08-30 2019-08-20 Council Of Scientific & Industrial Research Pro-Amb reverse turn restricted bioactive peptide analogues
KR102519166B1 (en) * 2016-10-07 2023-04-07 세카나 파머씨티컬스 지엠비에이치 엔 씨오. 케이지 Immunosuppression-restoring oligonucleotides that inhibit expression of CD39
EP4093409A4 (en) * 2020-01-23 2024-01-10 University of Southern California Antagonism as a therapy for tdp-43 proteinopathies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033869A2 (en) * 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1999057132A1 (en) * 1998-05-07 1999-11-11 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2001021831A1 (en) * 1999-09-21 2001-03-29 Al Mahmood Salman Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes
WO2001066742A2 (en) * 2000-03-03 2001-09-13 Incyte Genomics, Inc. G-protein coupled receptors
WO2001079556A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
JPH06141004A (en) 1992-10-27 1994-05-20 Mitsubishi Corp Charging system
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US5534913A (en) 1994-03-31 1996-07-09 At&T Corp. Apparatus and method for integrating downstream data transfer over a cable television channel with upstream data carrier by other media
WO2003029271A2 (en) * 2001-09-24 2003-04-10 Nuvelo Novel nucleic acids and polypeptides
DE102004058016B4 (en) * 2004-12-01 2014-10-09 Epcos Ag High-bandwidth surface acoustic wave device

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033869A2 (en) * 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1999057132A1 (en) * 1998-05-07 1999-11-11 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2001021831A1 (en) * 1999-09-21 2001-03-29 Al Mahmood Salman Method for identifying novel genes involved in the regulation of angiogenesis, study of said genes and use thereof for therapeutic purposes
WO2001066742A2 (en) * 2000-03-03 2001-09-13 Incyte Genomics, Inc. G-protein coupled receptors
WO2001079556A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_HUM [online] EMBL; 8 June 2001 (2001-06-08), "Homo sapiens clone MGC:14841 IMAGE:4295121", XP002223765, Database accession no. BC008502 *
DATABASE EMBL_SYN [online] EMBL; 18 March 1996 (1996-03-18), BRONDYK W H ET AL: "Cloning vector pCI-neo", XP002219165, Database accession no. U47120 *

Also Published As

Publication number Publication date
JP2005532788A (en) 2005-11-04
EP1566387A3 (en) 2006-04-19
EP1515742A2 (en) 2005-03-23
AU2003233359A8 (en) 2003-09-16
US20090264364A1 (en) 2009-10-22
JP4621762B2 (en) 2011-01-26
FR2836687A1 (en) 2003-09-05
AU2003233359A1 (en) 2003-09-16
US20050153917A1 (en) 2005-07-14
EP2161280A2 (en) 2010-03-10
EP1566387A2 (en) 2005-08-24
US7553492B2 (en) 2009-06-30
JP2009050262A (en) 2009-03-12
US8133877B2 (en) 2012-03-13
CA2477662A1 (en) 2003-09-12
EP2161280A3 (en) 2012-07-18
WO2003074073A2 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
WO2003074073A3 (en) Genes involved in regulating angiogenesis, pharmaceutical preparations containing same and applications thereof
WO2005097175A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
WO2007046834A3 (en) Glp-1 agonists, compositions, methods and uses
WO1998011234A3 (en) Human protein kinases
WO2006130639A3 (en) Novel glutamic acid decarboxylase (gad) chimera and methods of use
WO2007076319A3 (en) Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses
WO2005019259A3 (en) Variants of interleukin-1 receptor antagonist: compositions and uses thereof
DK1196442T3 (en) VGF polypeptides and methods for the treatment of VGF-related disorders
WO2004094651A3 (en) Novel human polypeptides encoded by polynucleotides
MXPA03000979A (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.
WO2003080105A3 (en) Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof
MXPA03010728A (en) B7 related protein-2 molecules and uses thereof.
WO2001059120A3 (en) Il-17 like molecules and uses thereof
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
WO2002070559A3 (en) Nuclear hormone receptor ligand binding domains
WO2001000662A3 (en) The use of human fgh-8 polypeptides as neurotrophic agents
WO2002044374A3 (en) Flea gaba receptor subunit nucleic acid molecules, proteins and uses thereof
WO2007081302A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2004101618A3 (en) Progestin-yol002c-cgi-45 receptor-related proteins
EP1634951A4 (en) Novel protein
WO2004003010A3 (en) Nuclear hormone receptor ligano-binding domain containing protein
WO2002033058A3 (en) Novel cysteine proteases and uses thereof
WO2004009633A8 (en) Serotonin receptor
WO2002070562A3 (en) Nuclear hormone receptor ligand binding domain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2477662

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003572589

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10934998

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003727567

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003727567

Country of ref document: EP